{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:13:59Z","timestamp":1780964039319,"version":"3.54.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T00:00:00Z","timestamp":1672704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T00:00:00Z","timestamp":1672704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Creating appropriate and sustainable treatment plans for patients with concurrent disorders presents a challenge to psychiatrists and addiction medicine specialists alike. Although varenicline has been found to be the most effective medication for smoking cessation and abstinence when compared to results from placebo medications, nicotine patches and bupropion, caution is needed when starting patients on this medication. With the high prevalence of concurrent mental health and substance use disorders in vulnerably-housed populations in Canada, it becomes increasingly important to advocate for increased guidance and research into treating concurrent disorders.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>In this case, a young female patient\u00a0provisionally diagnosed with bipolar I disorder was hospitalized for a manic episode in the context of substance use and medication noncompliance. She also endorsed a long history of tobacco, alcohol, cocaine, cannabis and ketamine use. Perceptual abnormalities, including auditory hallucinations, were not recorded at admission. In addition to being stabilized for bipolar diagnosis, the patient was started on nicotine replacement therapy on Day 7 of admission followed by initiation of varenicline for smoking cessation on Day 14 of admission. Soon after the varenicline treatment was started, the patient developed auditory hallucinations, paranoia and referential beliefs. However, her insight was intact, and she had minimal thought form disorganization. In this case, these symptoms were thought to be secondary to varenicline after the consideration of potential alternative contributors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The occurrence of side effects as a result of varenicline use in patients with diagnosed mental health conditions is rare and underlying psychiatric illness is not labeled as an absolute contraindication in the prescription of varenicline. However, it is important to advocate for increased guidance and research on the treatment of substance use disorders in patients with bipolar I disorder. Patients may also benefit from increased collaboration between psychiatric and addiction services as that may allow for earlier recognition and intervention of symptoms to minimize distress.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-022-04348-6","type":"journal-article","created":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T13:03:51Z","timestamp":1672751031000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Varenicline induced auditory hallucinations in a young female with bipolar disorder: a case report"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9401-008X","authenticated-orcid":false,"given":"Vivian W. L.","family":"Tsang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saundarai","family":"Bhanot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingsa","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,3]]},"reference":[{"issue":"1","key":"4348_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/15504263.2017.1392055","volume":"14","author":"L Zhang","year":"2018","unstructured":"Zhang L, Norena M, Gadermann A, Hubley A, Russell L, Aubry T, et al. Concurrent Disorders and Health Care Utilization Among Homeless and Vulnerably Housed Persons in Canada. J Dual Diagn. 2018;14(1):21\u201331. https:\/\/doi.org\/10.1080\/15504263.2017.1392055.","journal-title":"J Dual Diagn."},{"key":"4348_CR2","unstructured":"Canadian Centre on Substance Abuse. Substance abuse in Canada: concurrent disorders. Canadian Centre on Substance Abuse; 2009. 63. Available from: https:\/\/www.ccsa.ca\/substance-abuse-canada-concurrent-disorders."},{"key":"4348_CR3","unstructured":"Government of Canada Product Information. https:\/\/health-products.canada.ca\/dpd-bdpp\/info.do?lang=en&code=77655. Accessed 10 Mar\u00a02022."},{"key":"4348_CR4","doi-asserted-by":"publisher","unstructured":"Mihalak KB, Carroll FI, Luetje CW. Varenicline Is a Partial Agonist at 42 and a Full Agonist at 7 Neuronal Nicotinic Receptors. 2006; 70(3):801\u20135.\u00a0https:\/\/doi.org\/10.1124\/mol.106.025130.","DOI":"10.1124\/mol.106.025130"},{"key":"4348_CR5","doi-asserted-by":"publisher","unstructured":"Anthelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387(10037):2507\u201320. https:\/\/doi.org\/10.1016\/S0140-6736(16)30272-0.","DOI":"10.1016\/S0140-6736(16)30272-0"},{"issue":"1","key":"4348_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1177\/2045125311430111","volume":"2","author":"BB Annagur","year":"2012","unstructured":"Annagur BB, Bez Y. Varenicline-induced psychotic depressive episode in a patient with bipolar disorder. Therapeutic Adv Psychopharmacol. 2012;2(1):35\u20137. https:\/\/doi.org\/10.1177\/2045125311430111.","journal-title":"Therapeutic Adv Psychopharmacol"},{"key":"4348_CR7","doi-asserted-by":"publisher","unstructured":"Kohen KN. Varenicline-Induced Manic Episode in a Patient With Bipolar Disorder. 2007;164(8):1269\u201370. https:\/\/doi.org\/10.1176\/appi.ajp.2007.07010173.","DOI":"10.1176\/appi.ajp.2007.07010173"},{"key":"4348_CR8","unstructured":"Pfizer Medical Information Canada CHAMPIX (varenicline). https:\/\/www.pfizermedicalinformation.ca\/en-ca\/champix. Accessed 10 Mar\u00a02022."},{"issue":"7","key":"4348_CR9","doi-asserted-by":"publisher","first-page":"22106","DOI":"10.4088\/JCP.13m08756","volume":"75","author":"KNR Chengppa","year":"2014","unstructured":"Chengppa KNR, Perkins KA, Brar JS, Schlicht PJ, Turkin SR, Hetrick ML, et al. Varenicline for smoking cessation in bipolar disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014;75(7):22106. https:\/\/doi.org\/10.4088\/JCP.13m08756.","journal-title":"J Clin Psychiatry"},{"key":"4348_CR10","unstructured":"Martin DC. The Mental Status Examination. Clinical Methods: The History, Physical, and Laboratory Examinations. 1990; 924\u20139. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK320\/."},{"key":"4348_CR11","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.neubiorev.2021.11.039","volume":"132","author":"M Fornaro","year":"2022","unstructured":"Fornaro M, Carvalho AF, de Prisco M, Mondin AM, Billeci M, Selby P, et al. The prevalence, odds, predictors, and management of tobacco use disorder or nicotine dependence among people with severe mental illness: Systematic review and meta-analysis. Neurosci Biobehav Rev. 2022;132:289\u2013303. https:\/\/doi.org\/10.1016\/j.neubiorev.2021.11.039.","journal-title":"Neurosci Biobehav Rev"},{"issue":"2","key":"4348_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/WNF.0b013e31816f75bc","volume":"32","author":"F Alhatem","year":"2009","unstructured":"Alhatem F, Black JE. Varenicline-induced mania in a bipolar patient. Clin Neuropharmacol. 2009;32(2):117\u20138. https:\/\/doi.org\/10.1097\/WNF.0b013e31816f75bc.","journal-title":"Clin Neuropharmacol"},{"key":"4348_CR13","doi-asserted-by":"publisher","unstructured":"Kalarchian MA, Marcus MD. Exacerbation of Schizophrenia by Varenicline. 2007; 164(8):1269.\u00a0https:\/\/doi.org\/10.1176\/appi.ajp.2007.07020326.","DOI":"10.1176\/appi.ajp.2007.07020326"},{"issue":"1","key":"4348_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jad.2005.09.002","volume":"91","author":"M Varga","year":"2006","unstructured":"Varga M, Magnusson A, Flekk\u00f8y K, R\u00f8nneberg U, Opjordsmoen S. Insight, symptoms and neurocognition in bipolar I patients. J Affect Disord. 2006;91(1):1\u20139. https:\/\/doi.org\/10.1016\/j.jad.2005.09.002.","journal-title":"J Affect Disord."}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-022-04348-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-022-04348-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-022-04348-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T13:05:07Z","timestamp":1672751107000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-022-04348-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,3]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4348"],"URL":"https:\/\/doi.org\/10.1186\/s12888-022-04348-6","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,3]]},"assertion":[{"value":"7 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"An overseeing psychiatrist has ruled that the patient has been deemed capable of ethically and medically consenting for their participation in the research presented in this manuscript. Our procedure for the collection of consent is in line with IRB requirements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient signed written informed consent for the publication of this case report. Consent from the patient\u2019s power of attorney was not available as the patient did not have a power of attorney identified.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}